Literature DB >> 19404564

Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma.

Masato Narita1, Etsuro Hatano, Shigeki Arizono, Aya Miyagawa-Hayashino, Hiroyoshi Isoda, Koji Kitamura, Kojiro Taura, Kentaro Yasuchika, Takashi Nitta, Iwao Ikai, Shinji Uemoto.   

Abstract

BACKGROUND: Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) is an MRI contrast agent with perfusion and hepatoselective properties. The purpose of the study was to examine uptake of Gd-EOB-DTPA in the hepatobiliary phase in hepatocellular carcinoma (HCC).
METHODS: A retrospective analysis of 22 patients with HCC who underwent preoperative Gd-EOB-DTPA-enhanced MRI was performed. Enhancement ratios (ERs) and expression levels of the organic anion transporter (OATP) 1B3 protein were examined.
RESULTS: Gd-EOB-DTPA accumulated in the hepatobiliary phase in 6 of the 22 cases. All 6 Gd-EOB-DTPA-positive cases were moderately differentiated HCC, but 11 other moderately differentiated HCCs did not show Gd-EOB-DTPA uptake. Histopathologically, 4 Gd-EOB-DTPA-positive HCCs and 5 Gd-EOB-DTPA-negative HCCs produced bile. HCCs with Gd-EOB-DTPA uptake overexpressed OATP1B3 compared with HCCs without Gd-EOB-DTPA uptake, and OATP1B3 levels were significantly correlated with ERs (r=0.91, P<0.0001).
CONCLUSIONS: Uptake of Gd-EOB-DTPA in HCC is determined by expression of OATP1B3 rather than by tumor differentiation or bile production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404564     DOI: 10.1007/s00535-009-0056-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  17 in total

Review 1.  Contrast agents for MR imaging of the liver.

Authors:  R C Semelka; T K Helmberger
Journal:  Radiology       Date:  2001-01       Impact factor: 11.105

Review 2.  Pharmacogenomics of human OATP transporters.

Authors:  Jörg König; Annick Seithel; Ulrike Gradhand; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-03-09       Impact factor: 3.000

3.  Molecular determinants in the transport of a bile acid-derived diagnostic agent in tumoral and nontumoral cell lines of human liver.

Authors:  Antonin Libra; Cristina Fernetti; Vito Lorusso; Massimo Visigalli; Pier Lucio Anelli; Frantisek Staud; Claudio Tiribelli; Lorella Pascolo
Journal:  J Pharmacol Exp Ther       Date:  2006-08-08       Impact factor: 4.030

4.  Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1.

Authors:  J E van Montfoort; B Stieger; D K Meijer; H J Weinmann; P J Meier; K E Fattinger
Journal:  J Pharmacol Exp Ther       Date:  1999-07       Impact factor: 4.030

5.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.

Authors:  T Abe; M Unno; T Onogawa; T Tokui; T N Kondo; R Nakagomi; H Adachi; K Fujiwara; M Okabe; T Suzuki; K Nunoki; E Sato; M Kakyo; T Nishio; J Sugita; N Asano; M Tanemoto; M Seki; F Date; K Ono; Y Kondo; K Shiiba; M Suzuki; H Ohtani; T Shimosegawa; K Iinuma; H Nagura; S Ito; S Matsuno
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

6.  Abc protein transport of MRI contrast agents in canalicular rat liver plasma vesicles and yeast vacuoles.

Authors:  L Pascolo; S Petrovic; F Cupelli; C V Bruschi; P L Anelli; V Lorusso; M Visigalli; F Uggeri; C Tiribelli
Journal:  Biochem Biophys Res Commun       Date:  2001-03-23       Impact factor: 3.575

7.  Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.

Authors:  Kazuhiro Saito; Fumio Kotake; Naoki Ito; Taizo Ozuki; Ryuji Mikami; Kimihiko Abe; Yoko Shimazaki
Journal:  Magn Reson Med Sci       Date:  2005       Impact factor: 2.471

8.  Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging.

Authors:  B Hamm; T Staks; A Mühler; M Bollow; M Taupitz; T Frenzel; K J Wolf; H J Weinmann; L Lange
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

Review 9.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA.

Authors:  Christoph J Zech; Karin A Herrmann; Maximilian F Reiser; Stefan O Schoenberg
Journal:  Magn Reson Med Sci       Date:  2007       Impact factor: 2.471

10.  Prolonged positive contrast enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization.

Authors:  Y Ni; G Marchal; J Yu; A Mühler; G Lukito; A L Baert
Journal:  J Magn Reson Imaging       Date:  1994 May-Jun       Impact factor: 4.813

View more
  100 in total

1.  Prediction of the histopathological grade of hepatocellular carcinoma using qualitative diffusion-weighted, dynamic, and hepatobiliary phase MRI.

Authors:  Chansik An; Mi-Suk Park; Hyae-Min Jeon; Yeo-Eun Kim; Woo-Suk Chung; Yong Eun Chung; Myeong-Jin Kim; Ki Whang Kim
Journal:  Eur Radiol       Date:  2012-03-22       Impact factor: 5.315

2.  Signal profile on Gd-EOB-DTPA-enhanced MR imaging in non-alcoholic steatohepatitis and liver cirrhosis induced in rats: correlation with transporter expression.

Authors:  Natsuko Tsuda; Osamu Matsui
Journal:  Eur Radiol       Date:  2011-08-11       Impact factor: 5.315

3.  Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: a multicenter retrospective study.

Authors:  Tatsuo Inoue; Tomoko Hyodo; Keiko Korenaga; Takamichi Murakami; Yasuharu Imai; Atsushi Higaki; Takeshi Suda; Toru Takano; Kennichi Miyoshi; Masahiko Koda; Hironori Tanaka; Hiroko Iijima; Hironori Ochi; Masashi Hirooka; Kazushi Numata; Masatoshi Kudo
Journal:  J Gastroenterol       Date:  2015-09-15       Impact factor: 7.527

4.  Epigenetic regulation of organic anion transporting polypeptide 1B3 in cancer cell lines.

Authors:  Satoki Imai; Ryota Kikuchi; Yuri Tsuruya; Sotaro Naoi; Sho Nishida; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2013-06-28       Impact factor: 4.200

5.  Early hepatocellular carcinoma: definition and diagnosis.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

6.  Incidence for progression of hypervascular HCC in hypovascular hepatic nodules showing hyperintensity on gadoxetic acid-enhanced hepatobiliary phase in patients with chronic liver diseases.

Authors:  Megumi Matsuda; Takaharu Tsuda; Shinji Yoshioka; Shigetoshi Murata; Hiroaki Tanaka; Masashi Hirooka; Yoichi Hiasa; Teruhito Mochizuki
Journal:  Jpn J Radiol       Date:  2014-05-24       Impact factor: 2.374

Review 7.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

8.  Proper definitions of MRI contrast enhancement in liver tumors.

Authors:  Yicheng Ni; Feng Chen; Huaijun Wang; Yuanbo Feng; Junjie Li; Yansheng Jiang
Journal:  J Gastroenterol       Date:  2009-12-15       Impact factor: 7.527

9.  Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yuichiro Kubo; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Hiroshi Honda
Journal:  Eur Radiol       Date:  2014-07-26       Impact factor: 5.315

Review 10.  Pharmacogenetics of membrane transporters: an update on current approaches.

Authors:  Tristan M Sissung; Caitlin E Baum; C Tyler Kirkland; Rui Gao; Erin R Gardner; William D Figg
Journal:  Mol Biotechnol       Date:  2010-02       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.